首页 > 市场调查报告书 > 製药

癌症生物製剂

市场调查报告书

商品编码

1672131

全球癌症单株抗体市场研究报告-产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年

Global Cancer Monoclonal Antibodies Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年03月01日 | 出版商:

Value Market Research | 英文 163 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球癌症单株抗体市场规模预计将从 2024 年的 1,109.2 亿美元成长到 2033 年的 5,255.7 亿美元，在 2026 年至 2033 年的预测期内呈现 18.87% 的强劲年复合成长率(CAGR)。

受癌症发病率不断上升和标靶治疗需求不断增长的推动，癌症单株抗体市场正在经历显着增长。单株抗体（mAb）是专门针对癌细胞的工程蛋白质，与传统化疗相比，可提供更精确的治疗选择。随着医疗保健提供者和患者寻求有效且毒性较小的治疗替代方案，对癌症单株抗体的需求预计将上升，使该市场实现强劲扩张。目前的治疗方法包括曲妥珠单抗和利妥昔单抗等成熟的 mAb，以及针对各种癌症类型的较新药物。

此外，单株抗体技术的进步正在推动市场创新。双特异性抗体、抗体-药物偶联物和免疫检查点抑制剂的开发正在透过增强治疗的有效性和特异性彻底改变癌症治疗。这些创新不仅改善了治疗效果，而且还最大限度地减少了副作用，从而提高了患者的整体生活品质。随着研究不断探索单株抗体的新应用和组合，市场可能会进一步扩大，这得益于治疗方案的改善。

此外，对个人化医疗的日益重视正在塑造癌症单株抗体的模式。随着医疗保健提供者越来越认识到根据基因和分子特征为个别患者量身定制治疗方案的重要性，对符合个人化治疗策略的 mAb 的需求可能会上升。这一趋势在伴随诊断的背景下尤其重要，其中特定的生物标记可指导选择合适的单株抗体疗法。随着癌症单株抗体市场不断发展，创新疗法、个人化治疗和持续研究的结合将在推动其未来成长方面发挥关键作用。

我们的报告经过精心製作，为客户提供有关各个行业和市场的全面且可操作的见解。每份报告都包含几个关键部分，以确保彻底了解市场格局：

市场概览：市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本节探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准将市场细分为不同的细分市场。该分析强调了每个部分的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本节深入介绍领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，预测特定时期内的市场规模和成长趋势。这包括定量分析和图形表示来说明未来的市场轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前和新兴的市场趋势、技术创新和潜在投资领域。本节提供未来市场发展和成长前景的见解。

区域展望
介绍
北美销售分析
- 概述、历史和预测数据销售分析
- 北美各细分市场销售分析
- 北美各国销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概述、历史和预测数据销售分析
- 欧洲各细分市场销售分析
- 欧洲各国销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概述、历史和预测数据销售分析
- 亚太地区分部销售分析
- 亚太地区国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概述、历史和预测数据销售分析
- 拉丁美洲各细分市场销售分析
- 拉丁美洲各国销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概述、历史和预测数据销售分析
- 中东和非洲分部销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东和非洲其他地区销售分析

第 9 章：癌症单株抗体公司的竞争格局

癌症单株抗体市场竞争
伙伴关係/合作/协议
合併与收购
新产品发布
其他进展

第十章：公司简介

顶级公司市占率分析
市场集中度
F. Hoffmann-La Roche Ltd.

公司概况
公司收入
产品
最新动态

Bristol Myers Squibb Co.

公司概况
公司收入
产品
最新动态

Merck & Co.

公司概况
公司收入
产品
最新动态

GlaxoSmithKline Plc

公司概况
公司收入
产品
最新动态

Johnson & Johnson

公司概况
公司收入
产品
最新动态

Amgen Inc.

公司概况
公司收入
产品
最新动态

Novartis AG

公司概况
公司收入
产品
最新动态

AstraZeneca Plc

公司概况
公司收入
产品
最新动态

Eli Lilly And Company

公司概况
公司收入
产品
最新动态

AbbVie

公司概况
公司收入
产品
最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，对于私人公司，可能不予涵盖

简介目录图表

Product Code: VMR11216177

Global Cancer Monoclonal Antibodies Market size is anticipated to grow from USD 110.92 Billion in 2024 to USD 525.57 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 18.87% during the forecast period of 2026 to 2033.

The cancer monoclonal antibodies market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Monoclonal antibodies (mAbs) are engineered proteins designed to specifically target cancer cells, offering a more precise treatment option compared to traditional chemotherapy. As healthcare providers and patients seek effective and less toxic treatment alternatives, the demand for cancer monoclonal antibodies is expected to rise, positioning this market for robust expansion. Current therapies include well-established mAbs such as trastuzumab and rituximab, as well as newer agents that target various cancer types.

Moreover, advancements in monoclonal antibody technology are propelling innovation within the market. The development of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors is revolutionizing cancer treatment by enhancing the efficacy and specificity of therapies. These innovations not only improve treatment outcomes but also minimize side effects, thereby improving the overall quality of life for patients. As research continues to explore new applications and combinations of monoclonal antibodies, the market is likely to expand further, driven by the promise of improved therapeutic options.

Additionally, the growing emphasis on personalized medicine is shaping the cancer monoclonal antibodies landscape. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patient profiles based on genetic and molecular characteristics, the demand for mAbs that align with personalized treatment strategies is likely to rise. This trend is particularly relevant in the context of companion diagnostics, where specific biomarkers guide the selection of appropriate monoclonal antibody therapies. As the cancer monoclonal antibodies market continues to evolve, the combination of innovative therapies, a focus on personalized care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Type

Humanized
Human
Chimeric
Murine

By Application

Blood Cancer
Breast Cancer
Lung Cancer
Melanoma
Colorectal Cancer
Liver Cancer
Others

By End-user

Hospitals
Research Institutes
Others
COMPANIES PROFILED
F. Hoffmann-La Roche Ltd.
Bristol Myers Squibb Co.
Merck & Co.
GlaxoSmithKline plc
Johnson & Johnson
Amgen Inc.
Novartis AG
AstraZeneca plc
Eli Lilly and Company
AbbVie
The above list can be customized.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER MONOCLONAL ANTIBODIES INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Humanized Historic and Forecast Sales By Regions
5.4. Human Historic and Forecast Sales By Regions
5.5. Chimeric Historic and Forecast Sales By Regions
5.6. Murine Historic and Forecast Sales By Regions

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Blood Cancer Historic and Forecast Sales By Regions
6.4. Breast Cancer Historic and Forecast Sales By Regions
6.5. Lung Cancer Historic and Forecast Sales By Regions
6.6. Melanoma Historic and Forecast Sales By Regions
6.7. Colorectal Cancer Historic and Forecast Sales By Regions
6.8. Liver Cancer Historic and Forecast Sales By Regions
6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data Analysis By End-user
7.3. Hospitals Historic and Forecast Sales By Regions
7.4. Research Institutes Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER MONOCLONAL ANTIBODIES COMPANIES

9.1. Cancer Monoclonal Antibodies Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CANCER MONOCLONAL ANTIBODIES INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. F. Hoffmann-La Roche Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bristol Myers Squibb Co.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Merck & Co.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. GlaxoSmithKline Plc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Johnson & Johnson
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amgen Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Novartis AG
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. AstraZeneca Plc
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Eli Lilly And Company
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. AbbVie
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Type (USD MN)
Humanized Market Sales By Geography (USD MN)
Human Market Sales By Geography (USD MN)
Chimeric Market Sales By Geography (USD MN)
Murine Market Sales By Geography (USD MN)
Analysis By Application (USD MN)
Blood Cancer Market Sales By Geography (USD MN)
Breast Cancer Market Sales By Geography (USD MN)
Lung Cancer Market Sales By Geography (USD MN)
Melanoma Market Sales By Geography (USD MN)
Colorectal Cancer Market Sales By Geography (USD MN)
Liver Cancer Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By End-user (USD MN)
Hospitals Market Sales By Geography (USD MN)
Research Institutes Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Cancer Monoclonal Antibodies Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Cancer Monoclonal Antibodies Report
Market Research Process
Market Research Methodology
Global Cancer Monoclonal Antibodies Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Type
Market Attractiveness Analysis By Application
Market Attractiveness Analysis By End-user
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Type (USD MN)
Humanized Market Sales By Geography (USD MN)
Human Market Sales By Geography (USD MN)
Chimeric Market Sales By Geography (USD MN)
Murine Market Sales By Geography (USD MN)
Global Market Analysis By Application (USD MN)
Blood Cancer Market Sales By Geography (USD MN)
Breast Cancer Market Sales By Geography (USD MN)
Lung Cancer Market Sales By Geography (USD MN)
Melanoma Market Sales By Geography (USD MN)
Colorectal Cancer Market Sales By Geography (USD MN)
Liver Cancer Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By End-user (USD MN)
Hospitals Market Sales By Geography (USD MN)
Research Institutes Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.